Bioequivalence Study for Benzyl Alcohol Lotion 5%.

Completed · Phase 3 · Has a placebo group

Conditions studied: Head Lice

In brief

To establish the therapeutic equivalence and safety of a generic Benzyl Alcohol Lotion 5% with Ulesfia Lotion 5% in eradication of head lice in the study subjects.

Key facts

Study ID

NCT02624843

Run by

Akorn, Inc.

People needed

239

Starts

2015-08-01

Expected to finish

2015-11-01

Last updated by the study team

2021-01-27

Who can join

Age: 1 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy males or non-pregnant females aged 6 month or over with an upper age limit of 60 years.
• Prospective participants upon examination are confirmed to have at least 3 live head lice (defined as lice adults or nymphs) and at least 5 viable appearance louse eggs (nits).
• Prospective participants who give written informed consent or, if the participant is under 17 years of age, whose parent/guardian gives written informed consent to participate in the study.
• Prospective participants who will be available for follow up visits over the 21 days following first treatment.
• Prospective female participants (including female caregivers) of childbearing potential who are willing to provide a urine pregnancy test.
• Prospective participants who agree not to shave their hair or use any other pediculicide, nit combing, or louse treatment method during the course of the study.

You may not qualify if…

• Prospective participants with a known sensitivity to any of the ingredients in benzyl alcohol lotion 5% (Hi-Tech Pharmacal Inc) or Ulesfia 5% (Shionogi Inc).
• Prospective participants with a known history of irritation or sensitivity to pediculicides or hair care products.
• Prospective participants with a secondary bacterial infection of the scalp (eg. impetigo/pyoderma) or have a secondary or long term scalp condition that could make it difficult to evaluate the extent and severity of an infestation or that would present a problem in the evaluation of response to therapy (e.g., psoriatic lesions of the scalp, extensive seborrheic dermatitis).
• Prospective participants who have been treated with other head lice products within 4 weeks prior to randomization.
• Prospective participants who regularly shave their hair, have bleached their hair, used a permanent color on their hair, or their hair has been permanently straightened or waved within the previous 2 weeks.
• Prospective participants who have been treated with Trimethoprim containing products within the previous 4 weeks, or who are currently taking such a course.
• Females who are pregnant, planning to become pregnant, during the course of the study period, or are currently breast feeding mothers.
• Females of childbearing potential who are unwilling to use an adequate method of contraception from at least 4 weeks prior to the first application of treatment and until 4 weeks after the last application of treatment, or who are unwilling to take a urine pregnancy test.
• Prospective participants who have participated in another clinical study or used an investigational new drug within 1 month before entry into this study.
• Participants who have already participated in this clinical study.

Where it is running

• Axis Clinical Trials — Los Angeles, California, United States
• Axis Clinical Trials — Los Angeles, California, United States
• South Florida Family Health and Research Centers (Lice Source Services Inc) — Miami, Florida, United States
• South Florida Family Health and Research Centers (Lice Source Services Inc) — Plantation, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.